EN DE
Watch ADM Korea Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ADM Korea Inc. (187660) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of ADM Korea Inc. stock KRW 3,636, price KRW 6,010, that is 39.5% below the price, quality 35 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

AK ADM Korea Inc. logo Thin data Nov 10, 2026

ADM Korea Inc.

187660 · KQ
Very expensive, weak quality

Our calculation puts a fair price 39% below what the stock costs today.

Revenue last quarter 37% below a year ago.
Fair value 3,636 KRW · Strongly overvalued
Quality 35/100
Weak Growth (revenue 5y −6.7 %/yr in KRW)
Loss-making · -159.9% net margin (FY2025)
Negative free cash flow
Trails peers (0/9)
Narrow moat 7/100
Thin data
Estimate
Watch ADM Korea Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

18,101 KRW 854.13 KRW Fair Value 3,636 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 854.13 KRW – 18,101 KRW · fair‑value band 2,727 KRW – 4,545 KRW · the 6,010 KRW price screens above the 3,636 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow ADM Korea in your weekly email

Every Wednesday you see whether ADM Korea is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Penetrium Bioscience Inc., a contract research organization, provides clinical-related professional services for customer requirements in South Korea.

Show moreShow less

The company offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs.

It also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance services.

The company was formerly known as Hyundai ADM Bio Inc. and changed its name to Penetrium Bioscience Inc. in March 2026. Penetrium Bioscience Inc. was founded in 2003 and is based in Seoul, South Korea.

Stock analysis

ADM Korea Inc. (187660) currently trades at 6,010 KRW, while our estimate is 3,636 KRW, 39% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 2,727 KRW (bear) to 4,545 KRW (bull), the price of 6,010 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

ADM Korea Inc. reported revenue of 9.3B KRW in FY2025 versus 14.0B KRW in FY2021, a compound −9.8%/yr. Reported net income was −14.8B KRW in FY2025.

Key figures

Market cap 380B KRW (≈ $285M) Micro · P/S ratio 39.6 · EPS (TTM) −283.32 KRW · Return on equity −89.0% · Return on assets (EBIT) −15.8% (5-year average) · Operating margin −164% · Revenue (TTM) 9.7B KRW · Revenue growth (YoY) −37.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 7 out of 100 (medium confidence).

What moves the price

The share trades about 67% below its 52-week high and 163% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −39%, 187660 screens richer than that median.

Fair Value

Bear 2,727 KRW Fair Value 3,636 KRW Bull 4,545 KRW
Price 6,010 KRW · Downside -39.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 53
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 88
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 67
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 62
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
26.9% (2020) → −79.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

187660 screens overvalued: fair value 39% below the price. Compare with HCA Healthcare, Inc →

Compare ADM Korea Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks

Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −39.5% · Bottom 25%
Profitability
Return on assets −45.2% · Bottom 25%
Net margin (12 months) −159.9% · Bottom 25%
Operating margin (12 months) −164.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −37.2% · Bottom 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 17.67× · Priciest 25%
P/S (12 months) 39.03× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.74 $46.55 +105% vs 187660
Aier Eye Hospital Group 300015 ¥8.85 ¥10.88 +23% vs 187660
DaVita Inc DVA $179.28 $218.90 +22% vs 187660
HCA Healthcare, Inc HCA $504.42 $547.34 +9% vs 187660
Tenet Healthcare Corporation THC $290.27 $279.20 −4% vs 187660
The Ensign Group ENSG $185.09 $140.09 −24% vs 187660
Encompass Health Corporation EHC $142.51 $94.81 −33% vs 187660
Fresenius SE FRE €53.47 €34.77 −35% vs 187660
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,550 ₹5,234 −39% vs 187660
Dr. Sulaiman Al Habib Medical Services Group 4013 214.70 SAR 109.45 SAR −49% vs 187660

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ADM Korea Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ADM Korea Inc. Fair Value". https://www.fairvalue-calculator.com/stock/187660

Frequently asked questions

Is ADM Korea Inc. (187660) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 3,636 KRW versus a price of 6,010 KRW, about 39% lower (overvalued).
What is the fair value of 187660?
Our estimate for ADM Korea Inc. is 3,636 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 6,010 KRW.
What is the quality score of 187660?
ADM Korea Inc. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ADM Korea Inc. (187660)?
Our calculated price target is the estimate of 3,636 KRW (as of Nov 10, 2026). Cautious scenario 2,727 KRW, optimistic scenario 4,545 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the ADM Korea Inc. stock forecast for 2026?
Our estimate puts fair value at 3,636 KRW, about 39% lower versus a price of 6,010 KRW (overvalued). Cautious scenario 2,727 KRW, optimistic scenario 4,545 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ADM Korea Inc. (187660)?
ADM Korea Inc. reported trailing-twelve-month revenue of about 9.7B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of ADM Korea Inc. (187660)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ADM Korea Inc. it is 3,636 KRW per share (as of Nov 10, 2026), against a price of 6,010 KRW.
Is ADM Korea Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 187660 trades above its calculated fair value: price 6,010 KRW, fair value 3,636 KRW, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 187660?
No. The price is what the market pays today (6,010 KRW); the fair value is what the company's own numbers justify (3,636 KRW). For ADM Korea Inc. the two are 2,374 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ADM Korea Inc. worth?
The market values ADM Korea Inc. at about 380B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 6,010 KRW; our models calculate a fair value of 3,636 KRW per share.
What do the bullish and bearish scenarios say about 187660?
Our models span a range for ADM Korea Inc.: cautious scenario 2,727 KRW, base 3,636 KRW, optimistic 4,545 KRW per share (as of Nov 10, 2026, price 6,010 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ADM Korea Inc. (187660)?
Balance-sheet figures for ADM Korea Inc. (as of Nov 10, 2026): return on equity −89.0%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 187660 from its 52-week high?
ADM Korea Inc. trades at 6,010 KRW, about 67% below its 52-week high of 18,101 KRW and 163% above the low of 2,288 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 3,636 KRW is for.
Which stocks are comparable to ADM Korea Inc.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ADM Korea Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price 6,010 KRW, calculated fair value 3,636 KRW (−39%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. ADM Korea Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ADM Korea Inc. (187660)?
The closing price on Nov 10, 2026 was 6,010 KRW. Our estimate is 3,636 KRW, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ADM Korea Inc. right now?
The price sits above even our optimistic bull case (4,545 KRW). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of ADM Korea Inc.

How large is the market capitalisation of ADM Korea Inc. (187660)?
The market capitalisation of ADM Korea Inc. is 380B KRW (≈ $285M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ADM Korea Inc. (187660)?
The price-to-sales ratio of ADM Korea Inc. is 39.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ADM Korea Inc. (187660)?
Earnings per share at ADM Korea Inc. are −283.32 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ADM Korea Inc. (187660)?
The return on equity (ROE) of ADM Korea Inc. is −89.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ADM Korea Inc. (187660)?
On an EBIT basis the return on assets of ADM Korea Inc. is −15.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ADM Korea Inc. (187660)?
The operating margin of ADM Korea Inc. is −164% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ADM Korea Inc. (187660)?
Revenue at ADM Korea Inc. is growing −37.2% versus a year earlier (3y avg −14.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ADM Korea Inc. (187660) generate?
The free cash flow of ADM Korea Inc. is −5.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ADM Korea Inc. (187660) carry?
The net debt of ADM Korea Inc. is 220M KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ADM Korea Inc. in the live analysis

One click puts ADM Korea Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.